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Heart failure (HF) is a major public health problem with a lifetime risk of 
almost 1 in 3 to develop this disease.1,2 HF is the condition where the heart’s 
blood supply does not suffice the body’s demands. Despite improved 
treatment, the mortality rate for HF exceeds that of most malignancies.3 As the 
most energy-consuming organ in the body, failing energy metabolism is 
thought to play an important role in the development of HF.4 In this thesis, we 
investigated several aspects of metabolic interventions in HF. In the first part 
we investigated clinical aspects, including the position of β-blockers that have 
various metabolic effects. In this part we also describe the effect of coronary 
artery bypass grafting (CABG) in diabetic patients on HF development. In the 
second part we investigated the effects of A kinase interacting protein 1 
(AKIP1) on cardiac remodelling and metabolism. This potential mitochondrial 
target for HF treatment was investigated using a transgenic mouse model. 
 
Metabolic interventions after revascularization 
Several established therapies also affect cardiac metabolism. We focused on β-
blockers, that are known to have several metabolic “side-effects”, and it has 
been suggested that new onset diabetes and dyslipidaemia are possibly related 
to the use of β-blockers.5,6 Nevertheless, β-blockers have been recommended 
as first line therapy for stable coronary artery disease (CAD) for over 5 
decades, based on their potent anti-anginal effects and on extrapolation of the 
prognostic benefits that has been demonstrated after myocardial infarction 
(MI) and in patients with HF.7 CAD is a leading cause of morbidity and 
mortality worldwide and is the main cause of systolic HF.8 The lifetime risk of 
developing CAD is 30-50%.9 While mortality rates are decreasing by continued 
refinements in the treatment of acute coronary syndromes, innovation in the 
treatment of stable CAD has been limited. The studies supporting the efficacy 
of β-blockers in patients with CAD predate the current era of urgent coronary 
revascularisation and were specifically designed to evaluate their effects on 
angina. Of note, there is no evidence that β-blockers provide superior angina 
relief compared to calcium channel antagonists, nitrates or ivabradine. 
Furthermore, the evidence for the efficacy of β-blockers after revascularization 
in patients with stable CAD is sparse.7 Nevertheless, β-blockers are often 
continued in these patients, even when left ventricular function is preserved 
and there are no other indications for their continued use.10 In chapter 2 we 
therefore aimed to evaluate whether β-blocker therapy is associated with a 
reduced incidence of angina or cardiovascular events when continued after 
revascularization. For this purpose we performed a post-hoc analysis of the 
IMAGINE (Ischaemia Management with Acupril post bypass Graft via Inhibition 
of angiotensin coNverting Enzyme) trial database which comprised of low-risk 
patients with normal cardiac function, randomized to quinapril or placebo early 
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after elective coronary artery bypass grafting (CABG) surgery for CAD. This 
trail allowed us to study the low risk subgroup where we do not have evidence 
to support the routine use of β-blockers after CABG.  
In chapter 3, we sought to determine whether CABG reduces the 
propensity to develop HF in diabetic patients with CAD and preserved cardiac 
function. Patients with diabetes have a two-fold higher lifetime risk to develop 
HF.11,12 This is often linked to the propensity of diabetic patients to develop 
CAD and MI. Diabetic patients are also more prone to HF in the absence of 
CAD. The underlying mechanism is not completely clarified but is suggested to 
include increased oxidative stress and glycosylation leading to the activation of 
detrimental signal transduction pathways (Figure 1).13 Diabetes is an important 
risk factor for CAD and the extent of CAD is more severe in diabetic patients. 
This results in a higher frequency of MI and contributes to the two-fold higher 
lifetime risk to develop HF in diabetic patients (Figure1). Accordingly, CAD is 
treated aggressively in diabetic patients and the threshold for choosing CABG 
surgery over PCI is reduced.14,15 However, whether CABG also reduces the 




Figure 1 Pathophysiological links between diabetes and heart failure, adjusted 
from Dei Cas et al.13  
 
AKIP1 in cardiac stress 
Myocardial hypertrophy is the compensatory cardiac reaction to improve 
ventricular ejection performance after hemodynamic overload or injury. While 
initially myocardial hypertrophy reduces wall stress by restoring the ratio 
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between intracavitary pressure and wall thickness, it eventually 
decompensates and leads to HF.16,17 This pathological hypertrophy is 
accompanied by a gene expression profile that resembles the embryonic 
heart.18 Since it would be beneficial to only retain the adaptive aspects of 
physiological hypertrophy and prevent the deleterious collateral effects, we aim 
to determine what signaling pathways lead to hypertrophic decompensation. 
We previously performed genome wide transcription studies in a set of HF and 
hypertrophy models. We compared gene expression levels in 2 in vivo models 
(hypertension and post-MI) and 3 in vitro models in order to control for 
collateral differences in gene expression that are related to changes in 
hemodynamics rather than hypertrophic growth. One of the genes consistently 
upregulated was AKIP1.19 
AKIP1 is a 21 kDa protein that was first identified as Breast Cancer 
Associatated gene 3 (BCA3). In the initial studies, AKIP1 was found to be 
upregulated in several cancer cell lines, to tweak NF-κB and PKA activity,20,21 
and promote the induction of apoptosis.22,23 In contrast, AKIP1 stimulates 
neovascularisation and tumor growth in other malignancies.24,25 Therefore, 
AKIP1 may have different roles, depending on cell type and clinical condition. 
We previously performed several gain- and loss of function experiments of 
AKIP1 in cultured cardiomyocytes and found that AKIP1 promoted physiological 
growth in these cells.26 AKT-activation served as a mediator of AKIP1-induced 
physiological hypertrophy. Furthermore, we found that AKIP1 stimulates 
mitochondrial respiration while reducing mitochondrial ROS productions, 
arguably making respiration more efficient.27 In chapter 4 we will review in 
more detail how different aspects of metabolic dysfunction, like decreased 
energy supply and exacerbation of oxidative stress, lead to deteriorating HF. 
Another group found that AKIP1 attenuates ischemia / reperfusion (I/R) injury 
in ex vivo perfused hearts.28 Together, this suggests that AKIP1 has a vital role 
in both acute and chronic cardiac stress and that interventions targeting AKIP1 
could offer a viable strategy to treat patients with heart disease. To investigate 
this hypothesis, we generated a transgenic mouse line with cardiomyocyte 
specific overexpression of AKIP1. In chapter 5 & 6 we describe our studies 
exploring whether cardiac overexpression of AKIP1 translates into beneficial 
effects on both acute and chronic cardiac insults in vivo and whether it 




























Figure 2 AKIP1 might influence cardiac hypertrophy development in response to 
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